Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where E. Cinosi is active.

Publication


Featured researches published by E. Cinosi.


BioMed Research International | 2014

25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug

Francesco Saverio Bersani; Ornella Corazza; Gabriella Albano; Giuseppe Valeriani; Rita Santacroce; Flaminia Bolzan Mariotti Posocco; E. Cinosi; Pierluigi Simonato; Giovanni Martinotti; Giuseppe Bersani; Fabrizio Schifano

Introduction. The use of novel psychoactive substances (NPSs) has rapidly increased as well as their online availability. The aim of this paper is to provide a comprehensive review of the nature and the risks associated with 25C-NBOMe, which has recently appeared in the drug market. Methods. A systematic analysis of the scientific literature and a qualitative assessment of online and media resources (e.g., e-newsgroups, chat-rooms, and e-newsletters) in 10 languages were carried out. Results. 25C-NBOMe is sold online as legal LSD or as research chemical with different designations such as “Boom,” “Pandora,” “Holland film,” or “N-bomb.” It is a partial agonist of 5-HT2A receptors. It is usually ingested orally/sublingually and, less commonly, nasally, through injection, vaginally, rectally, and smoked. Its effects include sublingual numbing, stimulation, “body high,” hallucinations, dissociation, and anxiety. 25C-NBOMe presents high risk of overdoses; acute toxicity and fatalities have been reported. Conclusions. 25C-NBOMe consumption represents an emerging phenomenon with potential harmful effects. Its use is increased by its online availability at low costs. Health and other professionals should be informed about this new trend of substance use.


BioMed Research International | 2014

Novel Psychoactive Substances in Young Adults with and without Psychiatric Comorbidities

Giovanni Martinotti; M. Lupi; T. Acciavatti; E. Cinosi; Rita Santacroce; Maria Salvina Signorelli; Laura Bandini; Giulia Lisi; Diego Quattrone; Paola Ciambrone; Andrea Aguglia; Federica Pinna; Salvatore Calò; Luigi Janiri; Massimo Di Giannantonio

Objective. Comorbidities between psychiatric diseases and consumption of traditional substances of abuse (alcohol, cannabis, opioids, and cocaine) are common. Nevertheless, there is no data regarding the use of novel psychoactive substances (NPS) in the psychiatric population. The purpose of this multicentre survey is to investigate the consumption of a wide variety of psychoactive substances in a young psychiatric sample and in a paired sample of healthy subjects. Methods. A questionnaire has been administered, in different Italian cities, to 206 psychiatric patients aged 18 to 26 years and to a sample of 2615 healthy subjects matched for sex, gender, and living status. Results. Alcohol consumption was more frequent in the healthy young population compared to age-matched subjects suffering from mental illness (79.5% versus 70.7%; P < 0.003). Conversely, cocaine and NPS use was significantly more common in the psychiatric population (cocaine 8.7% versus 4.6%; P = 0.002) (NPS 9.8% versus 3%; P < 0.001). Conclusions. The use of novel psychoactive substances in a young psychiatric population appears to be a frequent phenomenon, probably still underestimated. Therefore, careful and constant monitoring and accurate evaluations of possible clinical effects related to their use are necessary.


Human Psychopharmacology-clinical and Experimental | 2015

Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas

Giovanni Martinotti; M. Lupi; Leonardo Carlucci; E. Cinosi; Rita Santacroce; T. Acciavatti; Eleonora Chillemi; Ludovica Bonifaci; Luigi Janiri; Massimo Di Giannantonio

Novel psychoactive substances (NPS) are new psychotropic drugs, not scheduled under the International Conventions on Psychotropic Substances, but which may pose a relevant public health threat. In this study, we investigated knowledge and use of NPS in a sample of Italian youth in urban and rural areas.


World Journal of Biological Psychiatry | 2017

Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition

Borwin Bandelow; David S. Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; S.R. Chamberlain; E. Cinosi; Simon J. Davies; Katharina Domschke; Naomi A. Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David J. Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M. Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer

Abstract Objective: Biomarkers are defined as anatomical, biochemical or physiological traits that are specific to certain disorders or syndromes. The objective of this paper is to summarise the current knowledge of biomarkers for anxiety disorders, obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD). Methods: Findings in biomarker research were reviewed by a task force of international experts in the field, consisting of members of the World Federation of Societies for Biological Psychiatry Task Force on Biological Markers and of the European College of Neuropsychopharmacology Anxiety Disorders Research Network. Results: The present article (Part II) summarises findings on potential biomarkers in neurochemistry (neurotransmitters such as serotonin, norepinephrine, dopamine or GABA, neuropeptides such as cholecystokinin, neurokinins, atrial natriuretic peptide, or oxytocin, the HPA axis, neurotrophic factors such as NGF and BDNF, immunology and CO2 hypersensitivity), neurophysiology (EEG, heart rate variability) and neurocognition. The accompanying paper (Part I) focuses on neuroimaging and genetics. Conclusions: Although at present, none of the putative biomarkers is sufficient and specific as a diagnostic tool, an abundance of high quality research has accumulated that should improve our understanding of the neurobiological causes of anxiety disorders, OCD and PTSD.


BioMed Research International | 2015

Following “the Roots” of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries

E. Cinosi; Giovanni Martinotti; Pierluigi Simonato; Darshan Singh; Zsolt Demetrovics; Andres Roman-Urrestarazu; Francesco Saverio Bersani; Balasingam Vicknasingam; Giulia Piazzon; Jih-Heng Li; Wen Jing Yu; Máté Kapitány-Fövény; Judit Farkas; Massimo Di Giannantonio; Ornella Corazza

The use of substances to enhance human abilities is a constant and cross-cultural feature in the evolution of humanity. Although much has changed over time, the availability on the Internet, often supported by misleading marketing strategies, has made their use even more likely and risky. This paper will explore the case of Mitragyna speciosa Korth. (kratom), a tropical tree used traditionally to combat fatigue and improve work productivity among farm populations in Southeast Asia, which has recently become popular as novel psychoactive substance in Western countries. Specifically, it (i) reviews the state of the art on kratom pharmacology and identification; (ii) provides a comprehensive overview of kratom use cross-culturally; (iii) explores the subjective experiences of users; (iv) identifies potential risks and side-effects related to its consumption. Finally, it concludes that the use of kratom is not negligible, especially for self-medication, and more clinical, pharmacological, and socioanthropological studies as well as a better international collaboration are needed to tackle this marginally explored phenomenon.


BioMed Research International | 2014

Pharmacological Treatments in Gambling Disorder: A Qualitative Review

M. Lupi; Giovanni Martinotti; T. Acciavatti; Mauro Pettorruso; Marcella Brunetti; Rita Santacroce; E. Cinosi; Giuseppe Di Iorio; Marco Di Nicola; Massimo Di Giannantonio

Gambling disorder (GD) is a psychiatric condition associated with both social and family costs; DSM-5 currently includes GD among addictive disorders. Despite the high burden of this condition, to date there are no treatment guidelines approved by Food and Drug Administration (FDA). Purpose of this paper is to offer a qualitative overview about the different pharmacologic agents used for the treatment of GD. Our analysis, conducted on a final selection of 75 scientific papers, demonstrates that a variety of pharmaceutical classes have been utilised, with different results. Published data, although limited by brief duration of the studies and small number of enrolled subjects, shows mixed evidence for serotonergic antidepressants, opioid antagonists, and mood stabilizers. Other compounds, such as glutamatergic agents and psychostimulants, deserve further studies.


BioMed Research International | 2014

Substance Use in the Club Scene of Rome: A Pilot Study

Alessandro Vento; Giovanni Martinotti; E. Cinosi; M. Lupi; T. Acciavatti; Rita Santacroce; Eleonora Chillemi; Ludovica Bonifaci; Massimo Di Giannantonio; Ornella Corazza; Fabrizio Schifano

Objective. Over the last few years, a wide number of unregulated substances have been marketed on the Web and in smart and head shops; they are usually advertised as legal alternatives to commonly known drugs and are defined as “smart drugs,” “legal highs,” and “novel psychoactive substances” (NPS). Aim of our work is to describe use habits and distribution of NPS in a population of young adults in Rome club scene. Methods. A self-administered questionnaire was proposed to subjects over 18 years of age at the entrance of 5 nightclubs in Rome. Socioeconomic characteristics and substance use were investigated. Results. Preliminary results give evidence that 78% of respondents have a lifetime history of NPS use. In addition, 56% of the sample has consumed illicit drugs in the past and 39% has used psychoactive substances in the 12 hours preceding the questionnaire administration. Conclusions. A significant proportion of subjects report use of novel psychoactive substances; traditional illicit drugs consumption, particularly cocaine, appears to be very high as well in the club scene. These data highlight a serious public health challenge, since pharmacological, toxicological, and psychopathological effects linked to interactions among all these substances may be unpredictable and sometimes fatal in vulnerable individuals.


Journal of Health Psychology | 2017

Alcohol drinking patterns in young people: A survey-based study:

Giovanni Martinotti; M. Lupi; Leonardo Carlucci; Rita Santacroce; E. Cinosi; T. Acciavatti; Fabiola Sarchione; Valeria Verrastro; Pierluigi Diotaiuti; Irene Petruccelli; S. Ferrari; Maria Giulia Nanni; Federica Pinna; Umberto Volpe; Aristide Saggino; Luigi Janiri; Lorenzo Leggio; Massimo Di Giannantonio

Binge drinking represents a major clinical and public health concern. Here, we investigated the prevalence of binge drinking and its related consequences, in a population of young adults. A questionnaire was administered to a sample of 4275 healthy subjects. In the overall sample, the percentage of binge drinkers was 67.6 per cent; among regular alcohol users, 79.5 per cent reported episodes of binge drinking. Among binge drinkers, several serious consequences were identified (staggering and stuttering, amnesia, loss of control, aggressiveness, sexual disinhibition). Raising awareness about the seriousness of binge drinking may help health care providers to identify cases early on and provide appropriate treatments.


BioMed Research International | 2014

New drugs on the Internet : the case of Camfetamine

E. Cinosi; Ornella Corazza; Rita Santacroce; M. Lupi; T. Acciavatti; Giovanni Martinotti; Massimo Di Giannantonio

Introduction. The number of new psychoactive substances (NPS) advertised for sale online is constantly increasing and it has become a phenomenon of global concern. Among NPS, Camfetamine has been rediscovered as recreational drug in 2011. Very little information is still available in the scientific literature on its nature and potential health risks. Methods. Data in scientific literature were integrated with a multilingual qualitative assessment of a range of online resources over the period of 32 months (May 2011–January 2014). Results. N-Methyl-3-phenyl-norbornan-2-amine (Camfetamine) may act as an indirect dopaminergic agonist in the central nervous system and may have mild-moderate opioid activity too. There are no current epidemiological data about recreational use of Camfetamine; our research shows that it is indeed used especially by individuals with a history of recreational polydrug misuse. It facilitates mental alertness, induces relaxation, and, unlike many other stimulants, seems not to be associated with severe physical effects. Valid causes for concern issued in our research may be Camfetamine intravenous or intramuscular administration as well as its use in conjunction with other psychoactive substances. Conclusions. It is here highlighted that more large-scale studies need to be carried out to confirm and better describe both the extent of Camfetamine misuse and possible psychotropic/adverse effects.


Neuropathology of Drug Addictions and Substance Misuse#R##N#Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions | 2016

Pregabalin Abuse and Addiction

G. Martinotti; Georgios Papazisis; Rita Santacroce; Dimitrios Kouvelas; E. Cinosi; M. Lupi; Massimo Di Giannantonio

Abstract Pregabalin, and its structurally related compound gabapentin, are known as α2δ ligands due to their interaction with the calcium (Ca2+) channel α2δ subunit. They may act as inhibitory modulators of neuronal excitability that reduce ectopic neuronal activation of hyperexcited neurons, while normal activation remains unchanged. The use of pregabalin is spreading in the therapeutic scenario; on the other hand, concerns about its potential for misuse and addiction are still to be cleared. Increasing levels of both prescriptions and related fatalities, together with an anecdotally growing black market, have been reported from a number of countries, drawing further attention on pregabalin misuse/abuse potential. Considering that pregabalin might be a new interesting therapeutic option in the field of addiction, it is of great clinical relevance to evaluate the abuse potential as an issue that should be taken into strong account, especially in subjects with a high-risk profile of misusing. The aim of this review is to analyze pregabalin pharmacology, clinical efficacy, and therapeutic use, as well as to present data on its abuse liability and addictive potential, reflecting on its pharmacological aspects.

Collaboration


Dive into the E. Cinosi's collaboration.

Top Co-Authors

Avatar

Rita Santacroce

University of Hertfordshire

View shared research outputs
Top Co-Authors

Avatar

M. Di Giannantonio

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stefano Marini

University of Chieti-Pescara

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ornella Corazza

University of Hertfordshire

View shared research outputs
Top Co-Authors

Avatar

Fabiola Sarchione

University of Chieti-Pescara

View shared research outputs
Top Co-Authors

Avatar

Federica Vellante

University of Chieti-Pescara

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge